/YCBD
YCBD Stock - cbdMD, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericAMEX
$1.51-21.76%
$0.42 (-21.76%) • Dec 19
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.82
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.31
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.66
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for YCBD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.49 – $1.53
TARGET (TP)$1.74
STOP LOSS$1.39
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.23
52W High$6.54
52W Low$0.47
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | $19.48M | $24.16M | $35.40M | $44.48M |
| Gross Profit | N/A | $12.00M | $14.98M | $22.34M | $29.99M |
| Gross Margin | N/A | 61.6% | 62.0% | 63.1% | 67.4% |
| Operating Income | N/A | $-3,189,572 | $-9,268,549 | $35.81M | $-19,615,991 |
| Net Income | $-4,375,403,000 | $-3,700,126 | $-22,938,209 | $-74,085,698 | $-23,394,889 |
| Net Margin | N/A | -19.0% | -95.0% | -209.3% | -52.6% |
| EPS | $-1.09 | $-1.79 | $-13.32 | $-55.80 | $-19.16 |
Company Overview
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
YCBDBeat Rate
25%
Last 16 quarters
Avg Surprise
-436.2%
EPS vs Estimate
Beats / Misses
4/12
Last 12 quarters
Latest EPS
$2.78
Q4 2025
EPS Surprise History
Q1 24
-624.3%
$-5.36vs$-0.74
Q2 24
-1340.0%
$-10.80vs$-0.75
Q3 24
-93.5%
$-1.20vs$-0.62
Q4 24
No data
Q1 25
-375.7%
$-1.76vs$-0.37
Q2 25
-18.7%
$-1.90vs$-1.60
Q3 25
-950.0%
$-0.21vs$-0.02
Q4 25
+4071.4%
$2.78vs$-0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | — | — | — | — |
Q4 2025 | Dec 19, 2025 | $-0.07 | $2.78 | +4071.4% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.02 | $-0.21 | -950.0% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-1.60 | $-1.90 | -18.7% | ✗ MISS |
Q1 2025 | Feb 13, 2025 | $-0.37 | $-1.76 | -375.7% | ✗ MISS |
Q4 2024 | Dec 27, 2024 | — | $-9.06 | — | — |
Q3 2024 | Aug 14, 2024 | $-0.62 | $-1.20 | -93.5% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.75 | $-10.80 | -1340.0% | ✗ MISS |
Q1 2024 | Feb 13, 2024 | $-0.74 | $-5.36 | -624.3% | ✗ MISS |
Q1 2024 | Jan 29, 2024 | $-0.74 | $-0.67 | +9.5% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-21.60 | $-9.28 | +57.0% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-28.80 | $-13.92 | +51.7% | ✓ BEAT |
Q1 2023 | Feb 13, 2023 | $-15.75 | $-28.83 | -83.0% | ✗ MISS |
Q4 2022 | Dec 15, 2022 | $-1.35 | $-90.09 | -6573.3% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-2.25 | $-7.21 | -220.4% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-4.05 | $-36.04 | -789.9% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $-11.53 | $-14.41 | -25.0% | ✗ MISS |
Q4 2021 | Dec 17, 2021 | — | $-14.41 | — | — |
Q3 2021 | Aug 12, 2021 | $-0.01 | $-0.01 | -75.1% | ✗ MISS |
Latest News
cbdMD shares are trading higher after the company reported better-than-expected Q4 sales results.
📈 PositiveBenzinga•Dec 19, 2025, 09:20 PM
cbdMD Q4 EPS $(0.08) Misses $(0.07) Estimate, Sales $4.721M Beat $4.702M Estimate
➖ NeutralBenzinga•Dec 19, 2025, 09:18 PM
cbdMD Shares Resume Trade
➖ NeutralBenzinga•Dec 19, 2025, 08:20 PM
cbdMD Raises $2.25M Through Series C Convertible Preferred Stock Financing
➖ NeutralBenzinga•Dec 19, 2025, 08:05 PM
cbdMD Shares Halted, News Pending
➖ NeutralBenzinga•Dec 19, 2025, 07:06 PM
'Trump's Marijuana Executive Order Details Leaked Ahead Of Announcement, Including CBD And Hemp Provisions'- Marijuana Moment
📈 PositiveBenzinga•Dec 18, 2025, 05:50 PM•Also: , ,
'Trump's Marijuana Rescheduling Order Could Include Industry Banking And CBD Medicare Coverage Provisions, Sources Say;'- Marijuana Moment
📈 PositiveBenzinga•Dec 17, 2025, 05:01 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher following reports suggesting President Trump will sign an executive order that will reclassify marijuana to a Schedule III drug.
📈 PositiveBenzinga•Dec 17, 2025, 02:38 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher after President Donald Trump confirmed his administration is strongly considering reclassifying marijuana.
📈 PositiveBenzinga•Dec 16, 2025, 07:17 PM•Also: , ,
cbdMD Regains NYSE American Compliance
📈 PositiveBenzinga•Dec 8, 2025, 04:10 PM
UPDATE: 'Medicare to Test Making CBD Treatment Available for Seniors' - Bloomberg News
📈 PositiveBenzinga•Nov 26, 2025, 05:58 PM•Also: , ,
cbdMD Sees Prelim. FY25 Net Sales $19.1M-$19.3M, Q4 Net Sales $4.7M-$4.9M
➖ NeutralBenzinga•Nov 21, 2025, 01:33 PM
cbdMD Announces New Partnership With Bevtalk Distribution To Expand Herbal Oasis THC Seltzer Distribution Across Florida
📈 PositiveBenzinga•Oct 9, 2025, 02:05 PM
On September 30, 2025 cbdMD Entered Into Securities Purchase Agreements With Four Institutional Investors For $1.7M Through 1.7M Series B Convertible Preferred Stock
📈 PositiveBenzinga•Oct 6, 2025, 08:51 PM
cbdMD Shares Halted On Circuit Breaker To the Upside, Stock Now Up 201.28%
📈 PositiveBenzinga•Sep 29, 2025, 02:44 PM
cbdMD Shares Halted On Circuit Breaker To The Upside, Stock Now Up 122.76%
📈 PositiveBenzinga•Sep 29, 2025, 02:20 PM
Maxim Group Maintains Buy on cbdMD, Lowers Price Target to $2
➖ NeutralBenzinga•Aug 20, 2025, 01:10 PM•Also:
Frequently Asked Questions about YCBD
What is YCBD's current stock price?
cbdMD, Inc. (YCBD) is currently trading at $1.51 per share. The stock has moved -21.76% today.
What is the analyst price target for YCBD?
No analyst price targets are currently available for this stock.
What sector is cbdMD, Inc. in?
cbdMD, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the AMEX exchange.
What is YCBD's market cap?
cbdMD, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does YCBD pay dividends?
No, cbdMD, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBFRI
Biofrontera Inc.
$0.77
Mkt Cap: $0.0B
CDIO
Cardio Diagnostics Holdings, Inc.
$3.23
Mkt Cap: $0.0B
EVOK
Evoke Pharma, Inc.
$11.00
Mkt Cap: $0.0B
FLGC
Flora Growth Corp.
$7.31
Mkt Cap: $0.0B
GBS
GBS Inc.
$0.47
Mkt Cap: $0.0B
MHUA
Meihua International Medical Technologies Co., Ltd.
$7.09
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
SBFM
Sunshine Biopharma, Inc.
$1.39
Mkt Cap: $0.0B
SNOA
Sonoma Pharmaceuticals, Inc.
$3.57
Mkt Cap: $0.0B
SSKN
STRATA Skin Sciences, Inc.
$1.19
Mkt Cap: $0.0B
Explore stocks similar to YCBD for comparison